Law Firm Investigates Forte Biosciences Sale to argenx BV
Monteverde & Associates PC has announced an investigation into the sale of Forte Biosciences, Inc. (NASDAQ: FBRX) to argenx BV. Shareholders are set to receive $77 per share. The firm is evaluating the fairness of the proposed transaction.
New York – July 27, 2026 – The law firm Monteverde & Associates PC announced today that it is investigating Forte Biosciences, Inc. (NASDAQ: FBRX) in connection with its sale to argenx BV. Under the terms of the proposed agreement, Forte Biosciences shareholders are expected to receive $77.00 per share in cash.
The firm, which has a track record of recovering funds for shareholders in class action lawsuits, is looking into the details of the transaction. Monteverde & Associates PC has been recognized for its work in securities litigation, including being named a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.
The investigation aims to determine if the proposed $77 per share offer adequately represents the value for Forte Biosciences shareholders. The firm is encouraging shareholders who own common stock in the company to contact them for more information regarding the sale and their rights.
Monteverde & Associates PC stated that there is no cost or obligation for shareholders to obtain information. They advise shareholders to consult with counsel to understand the specifics of the deal and ensure their potential interests are protected.